Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Genzyme provides update on U.S. LEMTRADA™ filing
Focal vibration in neurorehabilitation.
Antioxidant properties of the triaminopyridine, flupirtine.
Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
Dilantin
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study
Chemotherapeutics in the treatment of multiple sclerosis.
Receptos to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis
Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study.
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination.
Mitoxantrone-related acute leukemia in MS: An open or closed book?
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid.
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
Autoimmune Hepatitis-like reaction developing in a patient treated with Interferon beta 1a.
Gpr126 is essential for peripheral nerve development and myelination in mammals.
IFN-β inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis.
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Power estimation for non-standardized multisite studies.
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Interferon in relapsing-remitting multiple sclerosis.
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
New data from ENDORSE show positive results continued over five years with TECFIDERA® (dimethyl fumarate) in a wide range of multiple sclerosis patients

Pages